Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia

Detalhes bibliográficos
Autor(a) principal: Araújo, Aurigena Antunes de
Data de Publicação: 2012
Outros Autores: Chaves, Katarina Melo, Serrano-Blanco, Antoni, Ribeiro, Susana Barbosa, Soares, Luiz Alberto Lira, Guerra, Gerlane Coelho Bernardo, Alves, Maria do Socorro Costa Feitosa, Araújo Júnior, Raimundo Fernandes de, Rachetti, Vanessa de Paula Soares, Filgueira Júnior, Antônio
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Institucional da UFRN
Texto Completo: https://repositorio.ufrn.br/jspui/handle/123456789/25418
http://dx.doi.org/10.1007/s11126-012-9233-3
Resumo: This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.
id UFRN_50873dff70f5d72c7b9047330de8707a
oai_identifier_str oai:https://repositorio.ufrn.br:123456789/25418
network_acronym_str UFRN
network_name_str Repositório Institucional da UFRN
repository_id_str
spelling Araújo, Aurigena Antunes deChaves, Katarina MeloSerrano-Blanco, AntoniRibeiro, Susana BarbosaSoares, Luiz Alberto LiraGuerra, Gerlane Coelho BernardoAlves, Maria do Socorro Costa FeitosaAraújo Júnior, Raimundo Fernandes deRachetti, Vanessa de Paula SoaresFilgueira Júnior, Antônio2018-06-16T11:41:20Z2018-06-16T11:41:20Z2012-07-18ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018.1573-6709https://repositorio.ufrn.br/jspui/handle/123456789/25418http://dx.doi.org/10.1007/s11126-012-9233-3porSpringerSchizophreniaAtypical antipsychoticQuality of lifeQuality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophreniainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleThis cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTQuality of Life and Adverse Effects of Olanzapine_2013.pdf.txtQuality of Life and Adverse Effects of Olanzapine_2013.pdf.txtExtracted texttext/plain29140https://repositorio.ufrn.br/bitstream/123456789/25418/3/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.txt89c54f44dd5313b47ae527080965ccedMD53THUMBNAILQuality of Life and Adverse Effects of Olanzapine_2013.pdf.jpgQuality of Life and Adverse Effects of Olanzapine_2013.pdf.jpgIM Thumbnailimage/jpeg6155https://repositorio.ufrn.br/bitstream/123456789/25418/4/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.jpg185995c3e924d070e28b81363a784490MD54ORIGINALQualityLifeAdverseEffects_Araujo_2013.pdfQualityLifeAdverseEffects_Araujo_2013.pdfapplication/pdf199736https://repositorio.ufrn.br/bitstream/123456789/25418/1/QualityLifeAdverseEffects_Araujo_2013.pdf5e8f3cd29745cc2a999af56c4e9476e5MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25418/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/254182021-11-11 16:56:47.158oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T19:56:47Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false
dc.title.pt_BR.fl_str_mv Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
title Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
spellingShingle Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
Araújo, Aurigena Antunes de
Schizophrenia
Atypical antipsychotic
Quality of life
title_short Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
title_full Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
title_fullStr Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
title_full_unstemmed Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
title_sort Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia
author Araújo, Aurigena Antunes de
author_facet Araújo, Aurigena Antunes de
Chaves, Katarina Melo
Serrano-Blanco, Antoni
Ribeiro, Susana Barbosa
Soares, Luiz Alberto Lira
Guerra, Gerlane Coelho Bernardo
Alves, Maria do Socorro Costa Feitosa
Araújo Júnior, Raimundo Fernandes de
Rachetti, Vanessa de Paula Soares
Filgueira Júnior, Antônio
author_role author
author2 Chaves, Katarina Melo
Serrano-Blanco, Antoni
Ribeiro, Susana Barbosa
Soares, Luiz Alberto Lira
Guerra, Gerlane Coelho Bernardo
Alves, Maria do Socorro Costa Feitosa
Araújo Júnior, Raimundo Fernandes de
Rachetti, Vanessa de Paula Soares
Filgueira Júnior, Antônio
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Araújo, Aurigena Antunes de
Chaves, Katarina Melo
Serrano-Blanco, Antoni
Ribeiro, Susana Barbosa
Soares, Luiz Alberto Lira
Guerra, Gerlane Coelho Bernardo
Alves, Maria do Socorro Costa Feitosa
Araújo Júnior, Raimundo Fernandes de
Rachetti, Vanessa de Paula Soares
Filgueira Júnior, Antônio
dc.subject.por.fl_str_mv Schizophrenia
Atypical antipsychotic
Quality of life
topic Schizophrenia
Atypical antipsychotic
Quality of life
description This cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.
publishDate 2012
dc.date.issued.fl_str_mv 2012-07-18
dc.date.accessioned.fl_str_mv 2018-06-16T11:41:20Z
dc.date.available.fl_str_mv 2018-06-16T11:41:20Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018.
dc.identifier.uri.fl_str_mv https://repositorio.ufrn.br/jspui/handle/123456789/25418
dc.identifier.issn.none.fl_str_mv 1573-6709
dc.identifier.doi.none.fl_str_mv http://dx.doi.org/10.1007/s11126-012-9233-3
identifier_str_mv ARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018.
1573-6709
url https://repositorio.ufrn.br/jspui/handle/123456789/25418
http://dx.doi.org/10.1007/s11126-012-9233-3
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFRN
instname:Universidade Federal do Rio Grande do Norte (UFRN)
instacron:UFRN
instname_str Universidade Federal do Rio Grande do Norte (UFRN)
instacron_str UFRN
institution UFRN
reponame_str Repositório Institucional da UFRN
collection Repositório Institucional da UFRN
bitstream.url.fl_str_mv https://repositorio.ufrn.br/bitstream/123456789/25418/3/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.txt
https://repositorio.ufrn.br/bitstream/123456789/25418/4/Quality%20of%20Life%20and%20Adverse%20Effects%20of%20Olanzapine_2013.pdf.jpg
https://repositorio.ufrn.br/bitstream/123456789/25418/1/QualityLifeAdverseEffects_Araujo_2013.pdf
https://repositorio.ufrn.br/bitstream/123456789/25418/2/license.txt
bitstream.checksum.fl_str_mv 89c54f44dd5313b47ae527080965cced
185995c3e924d070e28b81363a784490
5e8f3cd29745cc2a999af56c4e9476e5
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)
repository.mail.fl_str_mv
_version_ 1797777062773129216